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During the EPI's first three decades of existence, they were fairly homogenous. The six basic antigens 1 included in the EPI were inexpensive and health system inputs, such as the human resources for vaccination and the vaccine supply chain and logistics infrastructure, accounted for the largest share of total costs in country programmes. 3 It was common knowledge that EPI vaccines represented 20% of overall investment in national immunization programmes in low-and lower-middle income countries. 4 With the turn of the millennium came a paradigm shift away from this earlier established trend as countries began introducing new vaccines, such as the pentavalent vaccine, a five-in-one combination of the antigens against diphtheria, tetanus and pertussis with those against hepatitis B (HepB) and Haemophilus influenzae type b (Hib).
pentavalent vaccine and, as a result, the total cost of country immunization programmes doubled or tripled. 5 Recurrent investments in vaccines suddenly comprised the bulk of immunization programme costs: an average of more than 50% of total investments, and in some cases, well over this average. 6 Part of the reason for this rise in the component of the total costs comprised by vaccines was that the incremental (i.e. non-vaccine) health system costs of introducing the pentavalent vaccine were marginal, since this product, despite adding two new antigens -HepB and Hib -to EPI schedules, required no more injections than the previously administered trivalent diphtheria-pertussis-tetanus (DPT) vaccine. In addition, pentavalent vaccines required little additional storage space in the vaccine cold chain. 7 Looking ahead, the current decade will see the accelerated introduction into national EPI programmes of additional new, expensive, but highly effective vaccines, such as pneumococcal conjugate vaccine and the vaccines against rotavirus and human papilloma virus (HPV). 3 These products, unlike the pentavalent vaccine, are bulkier than the pentavalent vaccine and will require more cold chain storage space and more injections. The health system costs associated with delivering these vaccines are likely to outweigh the costs of the vaccines themselves -which reverses the trend once again.
Investment in this decade
To gain insights into the investments needed to cover non-vaccine health system costs over the130146 decade from 2011 to 2020, a needs-based costing exercise was undertaken by the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) as part of the work done by a multi-partner group of experts. The group calculated the overall investment for vaccination that will be required in 94 low-and lower-middle-income countries over the period from 2011 to 2020, and the investment relative to 2010, the year used as the baseline. 8 The estimated non-vaccine costs to the health system of delivering routine vaccination will require an investment of 25.4 billion United States dollars (US$) during this decade (Fig. 1) . As countries sustain and scale up routine vaccination coverage, the investment on any given year during the decade will climb to a peak of roughly US$ 3.0 billion -twice the 2010 baseline estimate. The average health system cost per child (as measured by the number of infants in the birth cohort) will rise from US$ 18.1 at baseline (2010) to US$ 24.9 during the period from 2011 to 2015 and to US$ 32.6 from 2016 to 2020. This almost amounts to a doubling of total health system costs over the current decade and to a tripling of such costs relative to the previous decade.
In reviewing the annual trend over the decade from 2011 to 2020, the annual peak of US$ 3.0 billion observed midway suggests that capital investments in infrastructure should be front-loaded in the earlier years of the decade to ensure that countries are ready to introduce new vaccines as planned and to expand access to quality vaccination services. Such a profile is consistent with the expected performance targets and peaks in demand for pneumococcal, rotavirus and HPV vaccines, 8 as well as with estimates from the global investment framework for women and children's health. 9 A detailed review of the composition of costs reveals that investments in the components that are needed for service delivery represent 63% of total investments (Fig. 2) .
The remaining 37% is comprised by measures to ensure the uninterrupted availability of vaccines and supplies at the service delivery levels throughout vaccination supply chains. A deeper look into these cost categories underscores the importance of investing in human resources -for service delivery and supply chains -and in cold chain infrastructure, particularly at the subnational and service delivery levels. Together, these two cost categories represent nearly 70% of the overall US$ 25.4 billion required during this decade.
Human resources and supply chain strengthening
Like any public health programme, routine vaccination services critically depend on the skills and commitment of a strong, sufficient health workforce. Existing evidence points to a global shortage of health workers worldwide, and particularly in low-and lower-middle-income countries. 10 This shortage undermines the EPI because the need for human resource sharing in the health system is such that the same health worker is often expended across multiple programmes, including vaccination services. 11 It is no surprise that substantial increases in storage, distribution, handling and stock control. 13 Coupled with the growing complexities of this decades' EPI as newer vaccines and delivery strategies, as outlined in the GVAP, are deployed, vaccination supply chains are under intense pressure to adapt, innovate and scale up. Recent studies suggest that, if countries continue with "business as usual", vaccination supply chains will thwart the attainment of this decade's immunization goals. 14 The urgent need to address this bottleneck explains why this cost component represents the second largest non-vaccine cost driver.
Policy and practice implications
As the world celebrates the 40th anniversary of the launching of the EPI, many of the poorest countries are embarking on an ambitious strategy, in alignment with the GVAP. The purpose of the strategy is to sustain the achievements of past decades in the area of immunization and further expanding them by adopting new vaccines, reducing coverage gaps in routine vaccination by addressing inequities in access, and protecting people against vaccinepreventable diseases beyond childhood. 15 But in addition to investing in vaccines, it is critical to renew investments in strengthening the ability of health systems to deliver vaccines and From a policy and practice perspective, these findings highlight the fact that the backbone of routine immunization programmes in low-and lower-middle income countries during this decade is the imperative to strengthen human resources for immunization at all levels of the health system and to enhance the supply chain. The key challenge will be mobilizing the resources to finance non-vaccine immunization components in each country.
Doing so is no small feat. Securing funds to cover non-vaccine costs has always been more difficult than getting national or international funding to pay for the vaccines. According to projections of future financial flows for vaccination in 2011 to 2020, 65% of the need for Publication: Bulletin of the World Health Organization; Type: Perspectives Article ID: BLT.13.130146
Page 5 of 8 routine vaccination will not be met. 8 Strategies to fill the expected funding gaps are all the more pressing because of the impact that front-loading investments in earlier years would exert on countries' readiness to introduce new vaccines and because achieving certain infrastructural improvements can take several years. The EPI's continued success and the health and economic benefits to the health system that immunization will procure during the decade from 2011 to 2020 will hinge on sufficient financing of the needed investments in the non-vaccine components of routine vaccination services. Failing to mobilize adequate resources to finance these critical programme components will seriously compromise the ability of low-and lower-middle-income countries to meet the targets of this decade's Global
Vaccine Action Plan.
